
  
    
      
        Background_NNP
        Cyclosporine_NNP (_( CsA_NNP )_) and_CC tacrolimus_JJ (_( TAC_NNP )_) are_VBP the_DT primary_JJ
        immunosuppressive_JJ drugs_NNS used_VBN for_IN the_DT prevention_NN of_IN acute_JJ
        rejection_NN after_IN renal_JJ transplantation_NN ._. The_DT long-term_JJ
        treatment_NN of_IN patients_NNS with_IN either_DT CsA_NNP or_CC TAC_NNP results_NNS in_IN
        side_NN effects_NNS such_JJ as_IN nephrotoxicity_NN ,_, hypertension_NN ,_, and_CC
        gingival_NN hyperplasia_NN [_NN 1_CD 2_CD ]_NN ._. Sirolimus_NNP (_( SRL_NNP )_) a_DT new_JJ
        immunosuppressive_JJ agent_NN is_VBZ structurally_RB similar_JJ to_TO TAC_NNP
        binds_NNS to_TO same_JJ binding_JJ protein_NN FKBP_NNP ,_, but_CC its_PRP$ mechanism_NN of_IN
        action_NN is_VBZ different_JJ [_NN 3_CD ]_NN ._. Both_DT clinical_JJ and_CC experimental_JJ
        studies_NNS demonstrated_VBN that_IN SRL_NNP when_WRB used_VBN either_CC with_IN CsA_NNP or_CC
        alone_RB is_VBZ associated_VBN with_IN side_NN effects_NNS such_JJ as_IN
        hyperlipidemia_NN ,_, thrombocytopenia_NN and_CC nephrotoxicity_NN [_NN 4_CD 5_CD 6_CD
        7_CD ]_NN ._. Since_IN SRL_NNP and_CC TAC_NNP have_VBP affinity_NN for_IN the_DT same_JJ binding_JJ
        site_NN ,_, it_PRP was_VBD thought_VBN to_TO be_VB ineffective_JJ when_WRB used_VBN together_RB ._.
        However_RB ,_, experimental_JJ and_CC clinical_JJ studies_NNS have_VBP refuted_VBD
        this_DT assumption_NN ,_, and_CC have_VBP successfully_RB demonstrated_VBN the_DT
        efficacy_NN of_IN this_DT combination_NN therapy_NN [_NN 8_CD 9_CD 10_CD ]_NN ._.
        Encouraged_VBN by_IN our_PRP$ recent_JJ 
        in_IN vitro_NN study_NN [_NN 11_CD ]_NN that_WDT
        demonstrated_VBD a_DT significant_JJ inhibition_NN of_IN lymphocyte_NN
        proliferation_NN ,_, IL-_NNP 2_CD and_CC induction_NN of_IN TGF-β_NNP expression_NN by_IN
        combination_NN of_IN sub-clinical_JJ concentration_NN of_IN SRL_NNP with_IN
        either_DT TAC_NNP or_CC CsA_NNP ,_, we_PRP conducted_VBD the_DT current_JJ study_NN on_IN renal_JJ
        transplant_NN recipients_NNS ._. A_DT total_NN of_IN 10_CD stable_JJ renal_JJ
        transplant_NN recipients_NNS were_VBD selected_VBN to_TO participate_VB in_IN a_DT
        pharmacokinetic_JJ (_( PK_NNP )_) and_CC immune_JJ function_NN study_NN with_IN
        combination_NN of_IN TAC_NNP and_CC SRL_NNP therapy_NN in_IN human_JJ transplant_NN ._. The_DT
        current_JJ study_NN describes_VBZ the_DT analysis_NN of_IN immune_JJ function_NN in_IN
        stable_JJ renal_JJ transplant_NN recipients_NNS with_IN SRL_NNP and_CC TAC_NNP
        combination_NN therapy_NN ._.
      
      
        Methods_NNP
        
          Study_NN subjects_NNS /_NN Patients_NNPS
          Stable_NNP renal_JJ transplant_NN recipients_NNS receiving_VBG TAC_NNP based_VBD
          immunosuppression_NN were_VBD included_VBN in_IN this_DT study_NN ._. Definition_NNP
          of_IN "_'' stable_JJ "_'' transplant_NN patients_NNS is_VBZ based_VBN on_IN post_NN
          transplant_NN care_NN ,_, renal_JJ function_NN ,_, acute_JJ rejection_NN
          episodes_NNS ._. A_DT total_NN of_IN 10_CD patients_NNS were_VBD enrolled_VBN after_IN
          informed_VBN consent_NN ._. Azathioprine_NNP /_NN MMF_NNP (_( Mycophenolate_NNP
          Motefil_NNP )_) were_VBD discontinued_VBN prior_RB to_TO initiation_NN of_IN SRL_NNP and_CC
          all_DT patients_NNS were_VBD on_IN corticosteroids_NNS ._. On_IN day_NN zero_CD (_( 24_CD h_NN )_)
          after_IN discontinuation_NN of_IN Aza_NNP /_NN MMF_NNP )_) ,_, blood_NN samples_NNS were_VBD
          collected_VBN at_IN time_NN zero_CD (_( baseline_NN )_) and_CC 12_CD h_NN after_IN the_DT
          administration_NN of_IN TAC_NNP for_IN lymphocyte_NN proliferation_NN and_CC
          cytokine_NN expression_NN at_IN the_DT gene_NN and_CC protein_NN level_NN ._. SRL_NNP
          was_VBD started_VBN on_IN day_NN 0_CD and_CC patients_NNS were_VBD maintained_VBN on_IN the_DT
          same_JJ dose_NN of_IN TAC_NNP and_CC SRL_NNP for_IN 14_CD days_NNS ._. Blood_NNP samples_NNS were_VBD
          repeated_VBN on_IN day_NN 14_CD for_IN immune_JJ functions_NNS ,_, again_RB at_IN time_NN
          zero_CD (_( baseline_NN and_CC 12_CD h_NN after_IN )_) ._. The_DT graphic_JJ
          representation_NN of_IN the_DT treatment_NN protocol_NN is_VBZ shown_VBN in_IN
          figure_NN 1_CD ._. The_DT effect_NN of_IN this_DT concomitant_NN therapy_NN on_IN the_DT
          immune_JJ function_NN was_VBD studied_VBN by_IN quantifying_VBG lymphocyte_NN
          proliferation_NN and_CC the_DT mRNA_NN expression_NN of_IN TGF-β_NNP ,_, TNF-α_NNP ,_,
          IL-_NNP 10_CD ,_, IL-_NNP 6_CD ,_, IFN-γ_NNP by_IN RT-PCR_NNP assay_NN ._. Serum_NNP levels_NNS of_IN
          cytokines_NNS (_( IFN-γ_NNP ,_, TNF-α_NNP ,_, IL-_NNP 10_CD ,_, and_CC IL-_NNP 2_LS )_) were_VBD quantified_VBN
          by_IN a_DT cytokine_NN bead_NN array_NN system_NN and_CC TGF-β_NNP specific_JJ ELISA_NNP ._.
          Trough_NNP levels_NNS of_IN TAC_NNP and_CC SRL_NNP were_VBD not_RB available_JJ as_IN they_PRP
          were_VBD processed_VBN in_IN central_JJ core_NN laboratory_NN as_IN a_DT part_NN of_IN
          multicenter_NN study_NN ._.
        
        
          Preparation_NNP of_IN lymphocytes_NNS and_CC Experimental_NNP
          Protocol_NNP
          Peripheral_NNP blood_NN mononuclear_NN cells_NNS from_IN the_DT blood_NN of_IN
          renal_JJ transplants_NNS obtained_VBN at_IN time_NN zero_CD (_( day_NN #_# 0_CD )_) and_CC
          (_( day_NN #_# 14_CD )_) were_VBD separated_VBN by_IN ficoll-hypaque_JJ as_IN described_VBN
          by_IN earlier_JJR [_NN 11_CD ]_NN ._. Briefly_NNP ,_, lymphocytes_NNS were_VBD washed_VBN
          twice_RB in_IN Phosphate_NNP Buffered_NNP Saline_NNP (_( PBS_NNP )_) and_CC suspended_VBN in_IN
          RPMI_NNP containing_VBG 5_CD %_NN FBS_NNP and_CC Penicillin-_NNP Streptomycin_NNP ._.
          Lymphocytes_NNP were_VBD counted_VBN and_CC adjusted_VBN to_TO 1_CD ×_NN 10_CD 6_CD /_NN ml_NN and_CC
          200_CD ,_, 000_CD cells_NNS were_VBD plated_JJ in_IN a_DT 96_CD -_: well_RB plate_NN ._. Cells_NNP were_VBD
          cultured_JJ at_IN 37_CD C_NNP in_IN an_DT ambient_NN environment_NN with_IN 5_CD %_NN CO_NNP 2_CD
          air_NN with_IN PHA_NNP (_( 2_CD μg_NN /_NN ml_NN )_) ,_, ConA_NNP (_( 2_CD μg_NN /_NN ml_NN )_) and_CC anti-_NN CD_NNP 3_CD (_( 100_CD
          ng_NN /_NN ml_NN )_) for_IN 60_CD -_: 70_CD h_NN and_CC last_JJ 16_CD hours_NNS with_IN 3_CD H-_NNP thymidine_NN (_( 1_CD
          μCi_NN /_NN well_RB )_) ._. The_DT cells_NNS were_VBD then_RB harvested_VBN on_IN filter_NN papers_NNS
          using_VBG a_DT harvester_NN ,_, filter_NN papers_NNS were_VBD dried_VBN and_CC were_VBD then_RB
          transferred_VBN to_TO liquid_JJ scintillation_NN vials_NNS and_CC [_NN 3_CD H_NNP ]_NN
          thymidine_NN uptake_NN were_VBD quantified_VBN as_IN counts_VBZ per_IN minute_NN
          (_( CPM_NNP )_) using_VBG a_DT liquid_JJ scintillation_NN counter_NN ._.
        
        
          Detection_NNP of_IN mRNA_NN by_IN reverse_NN transcription_NN and_CC
          polymerase_NN chain_NN reaction_NN (_( RT-PCR_NNP )_)
          Total_NNP RNA_NNP was_VBD isolated_VBN from_IN lymphocytes_NNS isolated_VBN from_IN
          blood_NN obtained_VBN from_IN patients_NNS using_VBG Trizol_NNP isolation_NN
          System_NNP (_( Life_NNP Sciences_NNPS ,_, Invitrogen_NNP )_) and_CC quality_NN of_IN RNA_NNP was_VBD
          verified_VBN by_IN 260_CD /_NN 280_CD -_: nm_NN ratio_NN ._. 1_LS μg_NN of_IN RNA_NNP was_VBD reverse_VB
          transcribed_JJ to_TO cDNA_NN using_VBG Superscript_NNP First_CD Strand_NNP
          Synthesis_NNP system_NN for_IN RT-PCR_NNP (_( Life_NNP Technologies_NNPS Rockville_NNP
          MD_NNP ,_, USA_NNP )_) ._. The_DT amplification_NN by_IN polymerase_NN chain_NN reaction_NN
          (_( PCR_NNP )_) was_VBD carried_VBN out_IN using_VBG 1_CD μl_NN of_IN cDNA_NN ,_, and_CC 2_CD μl_NN each_DT
          of_IN 2_CD ._. 5_CD mM_NN coding_VBG and_CC non-coding_JJ oligonucleotide_NN primers_NNS
          and_CC Platinum_NN PCR_NNP Supermix_NNP (_( Life_NNP Technologies_NNPS Rockville_NNP
          MD_NNP ,_, USA_NNP )_) ._. The_DT primer_NN sequences_NNS of_IN TGF-β_NNP ,_, β-actin_JJ and_CC p_NN 21_CD
          are_VBP described_VBN in_IN our_PRP$ earlier_JJR studies_NNS [_NN 11_CD 12_CD ]_NN ._. The_DT
          primer_NN sequences_NNS for_IN other_JJ genes_NNS are_VBP :_: TNF-α_NNP ;_: coding_VBG
          5_CD '_POS -_: AAGAATTCAAACTGGGGCCT-_NNP 3_CD '_POS and_CC noncoding_VBG :_: 5_CD '_POS -_: GGCTACATGG_NNP
          GAACAG_NNP CCTA-_NNP 3_CD '_POS [_NN 13_CD ]_NN Cyclin_NNP G_NNP :_: coding_VBG
          5_CD '_POS -_: TGAAGCCTCAAAACATCACG-_NNP 3_CD '_POS and_CC noncoding_VBG 5_CD '_POS -_: CAGTGAT_NNP
          TGAAGCTGTG_NNP GGA-_NNP 3_CD '_POS [_NN 14_CD ]_NN ;_: Cyclin_NNP E_NNP :_: coding_VBG
          5_CD '_POS -_: TATACTTGCTGCTTC_NNP GGCCT-_NNP 3_CD '_POS and_CC non_NN coding_VBG
          5_CD '_POS -_: CTGCTCTGCTTC_NNP TTACCGCT-_NNP 3_CD '_POS [_NN 15_CD ]_NN ;_: IL-_NNP 6_CD :_: coding_VBG 5_CD '_POS
          ATGAACTCCTTCTC_NNP CACAAGCGC-_NNP 3_CD '_POS and_CC non_NN coding_VBG
          5_CD '_POS -_: GAAGAGCCCTCA_NNP GGCTGGACTGC-_NNP 3_CD '_POS [_NN 16_CD ]_NN ;_: IL-_NNP 10_CD :_: coding_VBG
          5_CD '_POS -_: AAGCCTGACCACGCTTTCTA-_NNP 3_CD '_POS ;_: and_CC non_NN coding_VBG 5_CD '_POS -_: CTCAGCCT_NNP
          CCCAAGT_NNP AGCTG-_NNP 3_CD '_POS [_NN 17_CD ]_NN ;_: IFN-γ_NNP :_: coding_VBG 5_CD '_POS -_: GCGAAAAAG_NNP
          GAGTCAGA_NNP TGC-_NNP 3_CD '_POS ;_: and_CC non_NN coding_VBG
          5_CD '_POS -_: TGGGATCTTGCTTAGGTTGG-_NNP 3_CD '_POS [_NN 18_CD ]_NN ;_: The_DT PCR_NNP products_NNS were_VBD
          resolved_VBN in_IN 1_CD %_NN agarose_NN gel_NN electrophoresis_NNS ,_, ethidium_NN
          bromide_NN stained_JJ specific_JJ bands_NNS will_MD be_VB visualised_JJ under_IN
          UV_NNP light_JJ and_CC photographed_VBN ._. The_DT densitometric_JJ analysis_NN of_IN
          the_DT specific_JJ bands_NNS was_VBD made_VBN using_VBG Alpha-_NNP Imager_NNP (_( Alpha_NNP
          Innotech_NNP Corp_NNP ._. San_NNP Leandro_NNP CA_NNP USA_NNP )_) and_CC data_NNS are_VBP
          represented_VBN as_IN the_DT ratio_NN of_IN the_DT specific_JJ gene_NN to_TO
          β-actin_JJ ._.
        
        
          Cytokine_NNP Bead_NNP Array_NNP
          We_PRP studied_VBD the_DT expression_NN of_IN circulating_VBG levels_NNS of_IN
          cytokines_NNS IFN-γ_NNP ,_, TNF-α_NNP ,_, IL-_NNP 10_CD ,_, IL-_NNP 5_CD ,_, IL-_NNP 4_CD and_CC IL-_NNP 2_CD in_IN
          sera_NN of_IN patients_NNS using_VBG a_DT new_JJ cytokine_NN bead_NN array_NN system_NN
          (_( BD_NNP Biosciences_NNP San_NNP Diego_NNP CA_NNP ,_, USA_NNP )_) ._. This_DT method_NN also_RB
          named_VBD multiplexed_JJ bead_NN assay_NN is_VBZ comprised_VBN of_IN spectrally_RB
          discrete_JJ particles_NNS ,_, which_WDT can_MD be_VB used_VBN to_TO quantitative_JJ
          soluble_JJ particles_NNS ,_, in_IN this_DT case_NN cytokines_NNS using_VBG a_DT
          fluorescence_NN based_VBD detection_NN mechanism_NN and_CC flowcytometric_JJ
          analysis_NN ._. The_DT beads_NNS coated_VBN with_IN IFN-γ_NNP ,_, TNF-α_NNP ,_, IL-_NNP 10_CD ,_,
          IL-_NNP 5_CD ,_, IL-_NNP 4_CD and_CC IL-_NNP 2_CD react_VB with_IN test_NN sera_NN and_CC standards_NNS ,_,
          to_TO which_WDT fluorescence_NN dyes_NNS are_VBP then_RB added_VBN ._. The_DT
          flowcytometric_JJ analysis_NN using_VBG special_JJ software_NN allows_VBZ the_DT
          calculation_NN of_IN concentrations_NNS in_IN the_DT unknown_JJ sera_NN ._.
        
        
          Quantification_NNP TGF-β_NNP protein_NN in_IN sera_NN
          Circulating_NNP levels_NNS of_IN TGF-β_NNP 1_CD protein_NN in_IN patients_NNS '_POS sera_NN
          were_VBD quantified_VBN using_VBG the_DT TGF-β_NNP specific_JJ ELISA_NNP (_( Promega_NNP ,_,
          Madison_NNP ,_, and_CC USA_NNP )_) ,_, as_IN described_VBN by_IN us_PRP earlier_JJR [_NN 11_CD ]_NN
          ._.
        
        
          Data_NNP Analysis_NNP
          Statistical_NNP analyses_NNS were_VBD performed_VBN by_IN using_VBG
          statistical_JJ program_NN purchased_VBN from_IN GraphPad_NNP Software_NNP ,_,
          Inc_NNP ._. (_( San_NNP Diego_NNP ,_, CA_NNP USA_NNP )_) ._. The_DT results_NNS are_VBP expressed_VBN as_IN
          Mean_VB ±_NN SEM_NNP and_CC a_DT two-tailed_JJ p_NN value_NN of_IN <_NN 0_CD ._. 05_CD was_VBD
          considered_VBN significant_JJ ._.
        
      
      
        Results_NNS
        
          Clinical_NNP Parameters_NNP
          The_DT mean_JJ age_NN of_IN patients_NNS included_VBN in_IN this_DT study_NN was_VBD 45_CD
          years_NNS (_( 32_CD -_: 56_CD years_NNS )_) ._. The_DT study_NN was_VBD conducted_VBN after_IN a_DT mean_JJ
          period_NN of_IN 49_CD months_NNS (_( 16_CD -_: 70_CD months_NNS )_) post-transplantation_JJ ._.
          The_DT mean_JJ plasma_NN creatinine_NN prior_RB to_TO SRL_NNP therapy_NN was_VBD 1_CD ._. 3_CD
          mg_NN /_NN dl_NN (_( 1_CD ._. 0_CD -_: 1_CD ._. 7_CD mg_NN /_NN dl_NN )_) and_CC was_VBD 1_CD ._. 2_CD mg_NN /_NN dl_NN (_( 0_CD ._. 9_CD -_: 1_CD ._. 6_CD mg_NN /_NN dl_NN )_)
          at_IN the_DT end_NN of_IN 14_CD days_NNS ._. The_DT mean_NN TAC_NNP dose_NN and_CC level_NN prior_RB
          to_TO SRL_NNP therapy_NN was_VBD 6_CD ._. 5_CD mg_NN /_NN day_NN (_( 4_CD -_: 10_CD )_) and_CC 8_CD ng_NN (_( 6_CD -_: 14_CD
          ng_NN /_NN ml_NN )_) ._. The_DT TAC_NNP dose_NN was_VBD not_RB adjusted_VBN during_IN the_DT study_NN
          period_NN and_CC mean_VB TAC_NNP level_NN at_IN 14_CD days_NNS was_VBD 6_CD ng_NN /_NN ml_NN (_( 4_CD -_: 13_CD
          ng_NN /_NN ml_NN )_) ._. None_NN of_IN these_DT recipients_NNS experienced_VBD acute_JJ
          rejection_NN or_CC any_DT other_JJ side_NN effects_NNS with_IN this_DT therapy_NN ._.
          The_DT exact_JJ SRL_NNP levels_NNS were_VBD not_RB available_JJ as_IN they_PRP were_VBD
          processed_VBN in_IN central_JJ core_NN laboratories_NNS ,_, however_RB were_VBD
          maintained_VBN at_IN therapeutic_JJ level_NN ._.
        
        
          Effect_NN of_IN concomitant_NN tacrolimus_JJ and_CC rapamycin_NN
          therapy_NN on_IN lymphocyte_NN proliferation_NN
          The_DT proliferation_NN of_IN lymphocytes_NNS from_IN patients_NNS treated_VBN
          with_IN TAC_NNP and_CC SRL_NNP were_VBD compared_VBN with_IN lymphocytes_NNS from_IN
          patients_NNS treated_VBN with_IN TAC_NNP and_CC MMF_NNP /_NN Aza_NNP ._. The_DT results_NNS are_VBP
          shown_VBN in_IN Figure_NN 2_CD which_WDT ,_, demonstrated_VBD a_DT significant_JJ
          inhibition_NN of_IN proliferation_NN of_IN lymphocytes_NNS from_IN patients_NNS
          with_IN TAC_NNP and_CC SRL_NNP compared_VBD to_TO TAC_NNP plus_CC MMF_NNP /_NN Aza_NNP ._. (_( PHA_NNP :_:
          17510_CD ±_NN 4094_CD vs_NNS 10963_CD ±_NN 3008_CD p_NN <_NN 0_CD ._. 05_CD ;_: ConA_NNP :_: 23995_CD ±_NN
          2449_CD vs_NNS 12124_CD ±_NN 2946_CD p_NN <_NN 0_CD ._. 006_CD ;_: and_CC anti-_NN CD_NNP 3_CD :_: 27089_CD ±_NN
          1557_CD vs_NNS 16093_CD ±_NN 3097_CD p_NN <_NN 0_CD ._. 005_CD )_) ._.
        
        
          Effect_NN of_IN concomitant_NN tacrolimus_JJ and_CC rapamycin_NN
          therapy_NN on_IN gene_NN expression_NN in_IN lymphocytes_NNS
          
            i_NNP )_) TGF-β_NNP mRNA_NN
            As_IN shown_VBN in_IN figure_NN 3_CD ,_, expression_NN of_IN TGF-β_NNP in_IN
            lymphocytes_NNS from_IN patients_NNS treated_VBN with_IN both_DT TAC_NNP and_CC SRL_NNP
            expressed_VBD as_IN ratio_NN with_IN β-actin_JJ (_( 0_CD ._. 9_CD ±_NN 0_CD ._. 12_CD )_)
            significantly_RB increased_VBN (_( p_NN <_NN 0_CD ._. 03_CD )_) ,_, when_WRB compared_VBN to_TO
            TAC_NNP and_CC MMF_NNP /_NN Aza_NNP (_( 0_CD ._. 5_LS ±_NN 0_CD ._. 12_CD )_) ._.
          
          
            ii_NN )_) p_NN 21_CD mRNA_NN expression_NN
            The_DT results_NNS are_VBP expressed_VBN as_IN ratio_NN of_IN p_NN 21_CD with_IN
            β-actin_JJ demonstrate_VB a_DT significant_JJ (_( p_NN <_NN 0_CD ._. 05_CD )_)
            increase_NN in_IN patients_NNS treated_VBN with_IN both_DT TAC_NNP and_CC SRL_NNP
            (_( 1_CD ._. 02_CD ±_NN 0_CD ._. 25_CD )_) ,_, when_WRB compared_VBN with_IN patients_NNS when_WRB they_PRP
            were_VBD treated_VBN with_IN TAC_NNP and_CC MMF_NNP /_NN Aza_NNP (_( 0_CD ._. 5_LS ±_NN 0_CD ._. 24_CD )_) {_( Figure_NN
            3_LS }_) ._.
          
          
            iii_NN )_) IL-_NNP 6_CD and_CC IL-_NNP 10_CD mRNA_NN
            Figure_NN 4_CD illustrates_VBZ comparison_NN of_IN the_DT IL-_NNP 6_CD and_CC IL-_NNP 10_CD
            mRNA_NN expression_NN in_IN patients_NNS treated_VBN with_IN TAC_NNP /_NN MMF_NNP /_NN Aza_NNP
            and_CC TAC_NNP /_NN SRL_NNP ._. The_DT results_NNS are_VBP expressed_VBN as_IN ratio_NN with_IN
            β-actin_JJ ,_, a_DT significant_JJ (_( p_NN <_NN 0_CD ._. 01_CD )_) increase_NN in_IN IL-_NNP 10_CD
            mRNA_NN in_IN patients_NNS treated_VBN with_IN both_DT TAC_NNP and_CC SRL_NNP (_( 0_CD ._. 84_CD ±_NN
            0_CD ._. 1_LS )_) ,_, when_WRB compared_VBN with_IN TAC_NNP and_CC MMF_NNP /_NN Aza_NNP (_( 0_CD ._. 47_CD ±_NN 0_CD ._. 1_LS )_) ._.
            Though_IN an_DT increase_NN in_IN IL-_NNP 6_CD mRNA_NN was_VBD observed_VBN in_IN renal_JJ
            transplant_NN recipients_NNS treated_VBN with_IN TAC_NNP /_NN SRL_NNP (_( 0_CD ._. 72_CD ±_NN 0_CD ._. 2_LS )_)
            compared_VBN to_TO patients_NNS treated_VBN with_IN TAC_NNP /_NN MMF_NNP /_NN Aza_NNP (_( 0_CD ._. 59_CD ±_NN
            0_CD ._. 16_CD )_) ,_, the_DT difference_NN was_VBD not_RB significant_JJ ._.
          
          
            iv_NN )_) TNF-α_NNP mRNA_NN
            We_PRP also_RB studied_VBD the_DT effect_NN of_IN SRL_NNP on_IN
            pro-inflammatory_JJ cytokine_NN TNF-α_NNP in_IN lymphocytes_NNS from_IN
            these_DT patients_NNS (_( Figure_NN 4_LS )_) ._. The_DT results_NNS expressed_VBD as_IN
            ratio_NN with_IN β-actin_JJ ,_, demonstrate_VBP a_DT marked_VBD decrease_NN (_( p_NN
            <_NN 0_CD ._. 05_CD )_) in_IN TNF-α_NNP levels_NNS in_IN lymphocytes_NNS from_IN patients_NNS
            treated_VBN with_IN TAC_NNP and_CC SRL_NNP (_( 0_CD ._. 22_CD ±_NN 0_CD ._. 08_CD )_) compared_VBN to_TO
            patients_NNS treated_VBN with_IN TAC_NNP /_NN MMF_NNP /_NN Aza_NNP (_( 0_CD ._. 11_CD ±_NN 0_CD ._. 05_CD )_) ._.
          
          
            v_NN )_) Cyclin_NNP mRNA_NN expression_NN
            The_DT results_NNS of_IN cyclins_NNS G_NNP and_CC E_NNP mRNA_NN expressed_VBD as_IN
            ratio_NN with_IN β-actin_JJ shown_VBN in_IN Figure_NN 5_CD ._. A_DT significant_JJ
            decrease_NN (_( p_NN <_NN 0_CD ._. 01_CD )_) in_IN Cyclin_NNP G_NNP mRNA_NN in_IN lymphocytes_NNS
            from_IN patients_NNS treated_VBN with_IN TAC_NNP and_CC SRL_NNP (_( 0_CD ._. 23_CD ±_NN 0_CD ._. 05_CD )_)
            compared_VBN to_TO patients_NNS treated_VBN with_IN TAC_NNP /_NN MMF_NNP /_NN Aza_NNP (_( 0_CD ._. 08_CD ±_NN
            0_CD ._. 01_CD )_) ._. Similarly_RB ,_, a_DT significant_JJ decrease_NN (_( p_NN <_NN 0_CD ._. 01_CD )_)
            in_IN Cyclin_NNP E_NNP mRNA_NN was_VBD noted_VBN with_IN TAC_NNP and_CC SRL_NNP (_( 0_CD ._. 2_LS ±_NN
            0_CD ._. 04_CD )_) compared_VBN to_TO TAC_NNP /_NN MMF_NNP /_NN Aza_NNP (_( 0_CD ._. 1_LS ±_NN 0_CD ._. 01_CD )_) ._. Combination_NNP
            of_IN decreased_VBD expression_NN of_IN cyclin_NN and_CC increased_VBN p_NN 21_CD
            mRNA_NN expression_NN correlates_NNS with_IN the_DT decreased_VBN
            lymphocyte_NN proliferation_NN ._.
          
        
        
          Circulating_NNP levels_NNS of_IN cytokines_NNS
          Combination_NNP of_IN TAC_NNP and_CC SRL_NNP resulted_VBD in_IN a_DT significant_JJ
          inhibition_NN of_IN cytokines_NNS in_IN sera_NN of_IN patients_NNS compared_VBN to_TO
          patients_NNS treated_VBN with_IN TAC_NNP /_NN MMF_NNP /_NN Aza_NNP ._. The_DT results_NNS shown_VBN in_IN
          Figure_NN 6_CD are_VBP expressed_VBN as_IN pg_NN /_NN ml_NN ;_: IFN-γ_NNP (_( 9_CD ±_NN 2_CD vs_NNS 6_CD ±_NN 1_CD ._. 6_CD ,_, p_NN
          <_NN 0_CD ._. 04_CD )_) ,_, IL-_NNP 4_CD (_( 7_CD ±_NN 0_CD ._. 35_CD vs_NNS 5_CD ._. 8_CD ±_NN 0_CD ._. 36_CD ,_, p_NN <_NN 0_CD ._. 02_CD )_)
          and_CC IL-_NNP 2_CD (_( 7_CD ±_NN 0_CD ._. 36_CD vs_NNS 6_CD ±_NN 0_CD ._. 26_CD p_NN <_NN 0_CD ._. 03_CD )_) without_IN any_DT
          change_NN in_IN the_DT levels_NNS of_IN TNF-α_NNP ,_, IL-_NNP 5_CD and_CC IL-_NNP 10_CD ._.
        
        
          TGF-β_NNP protein_NN expression_NN in_IN sera_NN of_IN patients_NNS
          Since_IN we_PRP observed_VBD a_DT significant_JJ increase_NN in_IN TGF-β_NNP mRNA_NN
          expression_NN in_IN lymphocytes_NNS from_IN patients_NNS treated_VBN with_IN
          combination_NN of_IN TAC_NNP and_CC SRL_NNP compared_VBD to_TO TAC_NNP /_NN MMF_NNP /_NN Aza_NNP ,_, we_PRP
          also_RB studied_VBD circulating_VBG levels_NNS of_IN total_JJ TGF-β_NNP protein_NN in_IN
          acid_NN activated_VBN sera_NN from_IN these_DT patients_NNS ._. The_DT results_NNS
          (_( figure_NN 7_CD )_) demonstrate_VB statistically_RB increased_VBN levels_NNS (_( p_NN
          <_NN 0_CD ._. 04_CD )_) of_IN TGF-β_NNP in_IN renal_JJ transplant_NN recipients_NNS after_IN
          addition_NN of_IN SRL_NNP to_TO TAC_NNP (_( 107_CD ±_NN 17_CD ._. 7_CD ng_NN /_NN ml_NN vs_NNS 135_CD ±_NN 18_CD
          ng_NN /_NN ml_NN )_) ._. These_DT results_NNS demonstrate_VBP that_WDT decreased_VBD
          lymphocyte_NN proliferation_NN in_IN part_NN may_MD be_VB due_JJ to_TO increased_VBN
          levels_NNS of_IN TGF-β_NNP in_IN these_DT patients_NNS ._.
        
      
      
        Discussion_NNP
        A_DT number_NN of_IN studies_NNS have_VBP demonstrated_VBN that_IN long_JJ
        treatment_NN of_IN both_DT CsA_NNP and_CC TAC_NNP is_VBZ associated_VBN many_JJ side_NN
        effects_NNS such_JJ as_IN nephrotoxicity_NN ,_, hypertension_NN ,_, and_CC gingival_NN
        hyperplasia_NN [_NN 1_CD 2_CD ]_NN ._. Rapamycin_NNP clinically_RB termed_VBD ,_, as_IN
        Sirolimus_NNP (_( SRL_NNP )_) is_VBZ a_DT new_JJ immunosuppressive_JJ agent_NN ,_, which_WDT is_VBZ
        structurally_RB similar_JJ to_TO TAC_NNP ,_, binds_NNS to_TO same_JJ binding_JJ protein_NN
        FKBP_NNP ,_, but_CC has_VBZ different_JJ mechanism_NN of_IN action_NN [_NN 3_CD ]_NN ._. Both_DT
        clinical_JJ and_CC experimental_JJ studies_NNS demonstrated_VBN that_IN SRL_NNP
        when_WRB used_VBN either_CC with_IN CsA_NNP or_CC alone_RB is_VBZ associated_VBN with_IN side_NN
        effects_NNS like_IN hyperlipidemia_NN ,_, thrombocytopenia_NN and_CC
        nephrotoxicity_NN [_NN 4_CD 5_CD 6_CD 7_CD ]_NN ._. SRL_NNP and_CC TAC_NNP compete_VBP for_IN the_DT
        same_JJ binding_JJ site_NN and_CC hence_RB it_PRP was_VBD thought_VBN they_PRP could_MD not_RB
        be_VB used_VBN concomitantly_RB ._. However_RB ,_, recent_JJ experimental_JJ and_CC
        clinical_JJ studies_NNS have_VBP refuted_VBD this_DT assumption_NN ,_, and_CC have_VBP
        successfully_RB used_VBN this_DT combination_NN therapy_NN [_NN 8_CD 9_CD 10_CD ]_NN ._.
        Therefore_RB there_EX is_VBZ need_NN of_IN an_DT alternate_JJ strategy_NN to_TO use_VB
        these_DT drugs_NNS to_TO treat_VB renal_JJ transplant_NN recipients_NNS ._. Recently_RB
        [_NN 11_CD ]_NN ,_, we_PRP have_VBP demonstrated_VBN the_DT efficacy_NN of_IN combination_NN
        of_IN low_JJ doses_NNS of_IN SRL_NNP with_IN either_DT CsA_NNP or_CC TAC_NNP to_TO inhibit_VB
        lymphocyte_NN proliferation_NN ._. The_DT results_NNS from_IN this_DT study_NN also_RB
        demonstrate_VB the_DT increased_VBN immuno_NN modulation_NN in_IN renal_JJ
        transplant_NN recipients_NNS by_IN this_DT therapy_NN ._. The_DT synergistic_JJ
        effect_NN of_IN SRL_NNP and_CC CsA_NNP has_VBZ been_VBN demonstrated_VBN in_IN animal_NN
        models_NNS and_CC clinical_JJ transplantation_NN [_NN 19_CD 20_CD ]_NN ._. This_DT
        prompted_VBD us_PRP to_TO explore_VB the_DT mechanistic_JJ action_NN of_IN SRL_NNP and_CC
        TAC_NNP when_WRB used_VBN in_IN combination_NN ._. Patients_NNS when_WRB received_VBD a_DT
        concomitant_NN therapy_NN of_IN TAC_NNP and_CC SRL_NNP exhibited_VBN a_DT significant_JJ
        inhibition_NN of_IN their_PRP$ lymphocytes_NNS when_WRB cultured_JJ with_IN
        mitogens_NNS ;_: PHA_NNP ,_, ConA_NNP and_CC anti-_NN CD_NNP 3_CD ,_, compared_VBN to_TO the_DT
        proliferation_NN of_IN lymphocytes_NNS obtained_VBN from_IN when_WRB they_PRP were_VBD
        treated_VBN with_IN TAC_NNP and_CC MMF_NNP /_NN Aza_NNP ._. Such_JJ a_DT sustained_VBN effect_NN is_VBZ
        expected_VBN to_TO prevent_VB graft_NN rejection_NN ,_, demonstrating_VBG the_DT
        efficacy_NN of_IN this_DT combination_NN in_IN renal_JJ transplant_NN
        recipients_NNS ._.
        To_TO analyse_NN the_DT mechanism_NN of_IN the_DT effect_NN of_IN concomitant_NN
        therapy_NN of_IN TAC_NNP and_CC SRL_NNP on_IN lymphocyte_NN proliferation_NN ,_, we_PRP
        studied_VBD the_DT mRNA_NN expression_NN of_IN TGF-β_NNP ,_, p_NN 21_CD ,_, IFN-γ_NNP ,_, TNF-α_NNP ,_,
        Il-_NNP 6_CD ,_, IL-_NNP 10_CD ,_, cyclins_NNS G_NNP and_CC E_NNP ._. The_DT results_NNS demonstrated_VBD a_DT
        significant_JJ increase_NN in_IN TGF-β_NNP mRNA_NN expression_NN (_( p_NN <_NN 0_CD ._. 03_CD )_)
        with_IN TAC_NNP and_CC SRL_NNP ._. The_DT expression_NN of_IN p_NN 21_CD mRNA_NN was_VBD also_RB
        increased_VBN in_IN renal_JJ transplant_NN recipients_NNS with_IN this_DT therapy_NN ._.
        These_DT results_NNS are_VBP consistent_JJ with_IN our_PRP$ previous_JJ studies_NNS [_NN 21_CD
        22_CD ]_NN ,_, that_IN TGF-β_NNP mediates_NNS in_IN part_NN the_DT immunosuppressive_JJ
        effects_NNS of_IN CsA_NNP and_CC TAC_NNP ._. Current_JJ study_NN supports_VBZ our_PRP$
        hypothesis_NNS that_IN the_DT immunosuppression_NN results_NNS in_IN an_DT
        increased_VBN expression_NN of_IN cyclin_NN inhibitor_NN p_NN 21_CD ,_, which_WDT by_IN
        inhibiting_VBG the_DT expression_NN of_IN cyclins_NNS controls_VBZ the_DT
        allo-immune_JJ activation_NN ._. Since_IN p_NN 21_CD is_VBZ one_CD of_IN the_DT most_RBS potent_JJ
        cyclin_NN inhibitor_NN ,_, these_DT results_NNS may_MD explain_VB the_DT significant_JJ
        inhibition_NN of_IN proliferation_NN of_IN lymphocytes_NNS may_MD in_IN part_VB be_VB
        due_JJ to_TO the_DT increased_VBN p_NN 21_CD expression_NN ._. The_DT expression_NN of_IN
        cyclin_NN E_NNP and_CC G_NNP ,_, which_WDT controls_VBZ the_DT cell_NN cycle_NN progression_NN
        and_CC G_NNP 0_CD /_NN S_NNP and_CC G_NNP 1_CD phase_NN of_IN cell_NN cycle_NN ,_, was_VBD decreased_VBN with_IN TAC_NNP
        and_CC SRL_NNP therapy_NN ._. The_DT expression_NN of_IN cyclins_NNS also_RB corresponds_NNS
        to_TO the_DT decreased_VBN lymphocyte_NN proliferation_NN with_IN SRL_NNP and_CC TAC_NNP
        therapy_NN ._.
        We_PRP noted_VBD an_DT increased_VBN expression_NN of_IN IL-_NNP 6_CD and_CC IL-_NNP 10_CD mRNA_NN
        in_IN lymphocytes_NNS from_IN patients_NNS with_IN concomitant_NN therapy_NN with_IN
        TAC_NNP and_CC SRL_NNP ._. A_DT number_NN of_IN experimental_JJ and_CC clinical_JJ studies_NNS
        [_NN 23_CD 24_CD ]_NN have_VBP demonstrated_VBN IL-_NNP 10_CD expression_NN to_TO be_VB
        beneficial_JJ and_CC correlates_NNS with_IN increased_VBN graft_NN survival_NN ._.
        The_DT results_NNS from_IN this_DT study_NN demonstrate_VB down_RB regulation_NN of_IN
        cyclins_NNS ,_, and_CC up-regulation_JJ of_IN cyclin_NN inhibitor_NN p_NN 21_CD and_CC
        IL-_NNP 10_CD mRNA_NN expression_NN ._.
        IL-_NNP 6_CD ,_, like_IN IL-_NNP 10_CD has_VBZ also_RB been_VBN considered_VBN to_TO possess_VB
        both_DT pro-_JJ and_CC anti-inflammatory_JJ properties_NNS [_NN 25_CD 26_CD ]_NN ._. In_IN
        this_DT study_NN ,_, we_PRP observed_VBD an_DT increase_NN in_IN mRNA_NN expression_NN of_IN
        IL-_NNP 6_CD ._. Acute_NNP rejection_NN has_VBZ been_VBN associated_VBN with_IN increased_VBN
        intragraft_NN IL-_NNP 6_CD protein_NN and_CC mRNA_NN production_NN [_NN 27_CD ]_NN ._.
        However_RB ,_, other_JJ studies_NNS have_VBP failed_VBN to_TO demonstrate_VB any_DT
        correlation_NN between_IN IL-_NNP 6_CD production_NN and_CC rejection_NN [_NN 28_CD ]_NN ._.
        The_DT current_JJ study_NN demonstrate_VB that_IN a_DT concomitant_NN therapy_NN of_IN
        TAC_NNP and_CC SRL_NNP increases_NNS expression_NN of_IN IL-_NNP 6_CD mRNA_NN in_IN
        lymphocytes_NNS and_CC its_PRP$ significant_JJ remains_VBZ to_TO be_VB
        evaluated_VBN ._.
        We_PRP also_RB quantified_VBN circulating_VBG levels_NNS of_IN TGF-β_NNP ,_, IL-_NNP 2_CD ,_,
        IL-_NNP 4_CD ,_, TNF-α_NNP ,_, and_CC IFN-γ_NNP ._. The_DT results_NNS from_IN this_DT study_NN
        demonstrate_VB that_DT addition_NN of_IN SRL_NNP to_TO TAC_NNP therapy_NN results_NNS in_IN
        a_DT significant_JJ (_( p_NN <_NN 0_CD ._. 04_CD )_) increase_NN in_IN circulating_VBG levels_NNS
        of_IN TGF-β_NNP ._. We_PRP have_VBP earlier_RBR demonstrated_VBN that_IN TGF-β_NNP in_IN part_NN
        mediates_NNS the_DT immunosuppressive_JJ effects_NNS of_IN these_DT drugs_NNS [_NN 11_CD
        12_CD 21_CD 22_CD ]_NN and_CC therefore_RB the_DT increased_VBN levels_NNS of_IN TGF-β_NNP may_MD
        partially_RB explain_VB the_DT increased_VBN inhibition_NN of_IN mitogen_NN
        induced_VBD lymphocyte_NN proliferation_NN ._. Though_IN the_DT role_NN of_IN TGF-β_NNP
        has_VBZ been_VBN correlated_JJ with_IN drug_NN induced_VBD nephrotoxicity_NN [_NN 29_CD ]_NN
        it_PRP is_VBZ early_JJ to_TO speculate_VB if_IN this_DT combination_NN will_MD also_RB
        result_VB in_IN an_DT increased_VBN nephrotoxic_JJ effects_NNS ._. We_PRP are_VBP unable_JJ
        to_TO demonstrate_VB the_DT nephrotoxicity_NN with_IN this_DT combination_NN due_JJ
        to_TO short_VB course_NN of_IN therapy_NN ._.
        The_DT levels_NNS of_IN IFN-γ_NNP ,_, IL-_NNP 4_CD and_CC IL-_NNP 2_CD were_VBD decreased_VBN
        substantially_RB with_IN SRL_NNP and_CC TAC_NNP therapy_NN {_( IFN-γ_NNP (_( p_NN <_NN
        0_CD ._. 04_CD )_) ,_, IL-_NNP 4_CD (_( p_NN <_NN 0_CD ._. 02_CD )_) and_CC IL-_NNP 2_CD (_( p_NN <_NN 0_CD ._. 03_CD )_) }_) ._. This_DT
        indicates_VBZ that_IN the_DT inhibition_NN of_IN lymphocyte_NN proliferation_NN
        with_IN SRL_NNP also_RB resulted_VBD in_IN decreased_VBD inflammatory_JJ
        response_NN ._.
      
      
        Conclusions_NNP
        In_IN conclusion_NN ,_, these_DT results_NNS provide_VBP evidence_NN to_TO
        potential_JJ efficacy_NN of_IN TAC_NNP and_CC SRL_NNP combination_NN therapy_NN in_IN
        renal_JJ transplant_NN recipients_NNS ._. The_DT addition_NN of_IN SRL_NNP to_TO the_DT
        immunosuppressive_JJ regimen_NN of_IN Tac_NNP resulted_VBD in_IN decreased_VBD
        lymphocyte_NN proliferation_NN exhibiting_VBG decreased_VBN allo-immune_JJ
        response_NN ._. Also_RB ,_, mRNA_NN expression_NN of_IN proinflammatory_NN
        cytokines_NNS TNF-α_NNP ,_, Interferon-γ_NNP and_CC cyclins_NNS G_NNP 1_CD ,_, and_CC E_NNP were_VBD
        significantly_RB decreased_VBN and_CC the_DT expression_NN of_IN TGF-β_NNP and_CC p_NN 21_CD
        were_VBD increased_VBN ._. The_DT addition_NN of_IN SRL_NNP significantly_RB decreased_VBD
        the_DT circulating_VBG levels_NNS of_IN pro-inflammatory_JJ cytokines_NNS and_CC
        conversely_RB increased_VBD the_DT circulating_VBG levels_NNS of_IN TGF-β_NNP ,_,
        partially_RB explaining_VBG the_DT increased_VBN immunosuppression_NN in_IN
        these_DT patients_NNS ._. However_RB ,_, due_JJ to_TO short_VB span_NN of_IN this_DT
        treatment_NN ,_, the_DT nephrotoxic_JJ effects_NNS remains_VBZ unclear_JJ ._. These_DT
        novel_NN findings_NNS provide_VBP a_DT mechanism_NN and_CC rationale_NN for_IN a_DT
        concomitant_NN therapy_NN with_IN TAC_NNP and_CC SRL_NNP in_IN renal_JJ transplant_NN
        patients_NNS ._.
        Author_NN 1_CD initials_NNS AK_NNP planned_VBD and_CC carried_VBN out_RP all_PDT the_DT
        studies_NNS with_IN the_DT help_NN of_IN Author_NN 2_CD initials_NNS MP_NNP ,_, Author_NN 3_CD
        initials_NNS CB_NNP assisted_VBN in_IN collecting_VBG blood_NN samples_NNS ._. Author_NN 4_CD
        initials_NNS JW_NNP carried_VBD out_RP Cytokine_NNP Bead_NNP Array_NNP analysis_NN for_IN
        serum_NN cytokine_NN levels_NNS and_CC Author_NN 5_CD initials_NNS S_NNP H_NNP recruited_VBD
        patients_NNS for_IN this_DT study_NN and_CC clinically_RB managed_VBD these_DT
        patients_NNS ._.
      
    
  
